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                         Abstract  
  
This research project, undertaken for a MPH dissertation investigated and analysed the situation 
of diabetes and diabetic retinopathy services and management systems in four (4) government 
hospitals in Akwa Ibom State Nigeria using the World Health Organisation  
(WHO) Tool for the Assessment of Diabetic Retinopathy and Diabetes Management Systems  
(TADDS).   
Part A is the research protocol, which explains the background and the key components of 
this research study. This is a cross sectional descriptive case study involving primary data 
collection. We conducted the case study using the WHO TADDS to survey health personnel 
involved in the management of diabetes mellitus (DM) and diabetic retinopathy (DR) in four 
(4) government hospitals in Akwa Ibom State. Concurrently, semi-structured interviews were 
conducted with key informants to investigate and analyse the situation of DM and DR 
services in Akwa Ibom State in Nigeria.   
Part B is a structured literature review of published articles, online reports, and summaries 
related to DR. It covers the review of scientific evidence (clinical overview) about the aetiology 
and prevention of DR and the known risk factors; the review of epidemiological evidence on 
DM and DR globally and in sub-Saharan Africa (SSA); and the review of the evidence on 
effectiveness and cost-effectiveness of public health and health system interventions for the 
prevention and management of DR.   
Part C is the journal-ready manuscript. In this part, the format of the journal Ophthalmic  
Epidemiology was used to present the research project and its main findings.    
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1.0          Purpose of study  
  
1.1             Primary objective  
  
The primary objective of this study is to investigate the situation of diabetes mellitus (DM) and 
diabetic retinopathy (DR) services in government hospitals in Akwa Ibom  
State (AKS) Nigeria using the World Health Organisation (WHO) Tool for the Assessment of 
Diabetes and Diabetic Retinopathy Management Systems (TADDS).   
 
 1.2            Secondary Objectives   
  
The secondary objectives of this study are as follows:  
I. To investigate the referral pathways between diabetes and eye care services in AKS.   
II. To identify the cadres of staff, their distribution, and number as well as the training of 
staff included in the DM and DR services in AKS.   
III. To explore the challenges faced by different cadres of staff involved in DM and DR 
services in AKS.  
IV. To explore and describe the follow-up systems for patients with DM and DR in AKS. 
V.  To describe the policies and programmes on DM and DR services in AKS.  










2.0            Background   
  
Diabetes mellitus (DM) is one of the commonest non-communicable diseases (NCDs) 
worldwide and has become a major public health problem.1, 2  
In the year 2000, the total number of people with diabetes for all age-groups was 171 million 
worldwide.3 Presently, about 500 million people live with diabetes, 425 million of those people 
are between the ages of 20 to 79.4 It is estimated that by 2045, the number of people with DM 
will be 629 million.4 In sub-Saharan Africa (SSA), the prevalence of DM was estimated to be 
19.8 million in 2013 and by 2035 it is projected that the number will increase to 41.4 million, 
yet public health approaches required to combat the developing epidemic of DM are limited or 
not existing at all.5  
About 80% of the global DM burden is in low and middle-income countries. “Rapid 
urbanization, unhealthy diets and increasingly sedentary lifestyles have resulted in previously 
unheard-of rates of obesity and diabetes, and many countries do not have adequate resources 
to provide preventive or medical care for their populations”.6, 7  
Findings from the survey carried out in Nigeria in 2003 reported that prevalence of DM was 
6.8% for individuals who are 40 years and above,8 while in individuals aged 15 years and above  
the prevalence varied from 1.6% to 12.7%. 5, 9-12  
In 2014, Nigeria was estimated to have 4 million diabetes patients, a fifth of all SSA diabetes 
cases.13 However, 70% - 80% of the 4 million as estimated in 2014 remained undiagnosed or 
untreated.13 This resulted into many patients presenting to the secondary and tertiary health 
care centres with the disease already at an advanced stage.14 “Poverty, unawareness, attribution 
of symptoms to other myths, lack / inadequate tools and basic infrastructure, inadequate 
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training of health workers were shown to be factors responsible for most of the failures to detect 
DM, increased risk of misdiagnosis and late diagnosis of patients at complication stages of the 
disease”.15  
DM can present acute and chronic severe complications which can lead to incapacitation and 
death.16  
Diabetic retinopathy (DR) may be the commonest and potentially most blinding of all the 
complications.17-19 DR is diabetes-related structural and functional damage to the retina.20 DR 
is a progressive condition and is potentially vision threatening.21 The underlying pathogenesis 
is because microangiopathy and capillary occlusion.22  
Globally, DR accounts for 5% of all blindness23 and cause visual impairment for 4.2 million 
people.2 DR is one of  the leading cause of blindness in people aged 15 – 64 years in developed 
countries.24 DR is responsible for most blindness amongst the working population in the USA.20 
It has become a significant cause of blindness in the developing world with the near pandemic 
situation of DM in the world.7 DR has few ophthalmic symptoms until visual loss occurs.20 Up 
to 21% of DM patients have  DR at the first time of diagnosis of DM.25, 26  
DR can be non-proliferative (NPDR) or proliferative (PDR)27. PDR is sight-threatening which 
can lead to visual impairment and even to blindness.26   
Poor control of blood sugar, high blood pressure and having DM for a long time have been 
reported as risk factors for DR,26 however, clinical trials have reported that early treatment of 
DR can preserve vision.25  
DR affects about 55% of all DM cases at diagnosis, with a high proportion of PDR and macula 
oedema (DME).28  
6  
  
It has been reported also that DR is common among patients who have suffered DM for 15 
years or more, and also common in patients with non-insulin dependent diabetes (type 2) 
compared to patients with insulin dependent diabetes (type 1).29  
Similarly, Omolase et al. (2010) reported that among DM patients attending a tertiary health 
centre in Ondo State, Nigeria, 85% had T2DM, while 15% had T1DM.  Varying degrees of DR 
was present in 15% of the respondents and the development of DR had a significant association 
with the duration of DM.30   
Azuamah et al. (2013) reported that in South Eastern Nigeria, DR contributed 1.12% of the 
total blindness among adults with the average age of 59 years. This made DR the fifth more 
common cause of blindness in this zone.31   
  
In 2010, a study among patients with DM in AKS aged 19 to 82 years revealed that 94.5% of 
the patients had T2DM, 4.6% had T1DM and 0.9% had gestational DM. The prevalence of DR 
was 52.7% while 36.7% of patients presented no signs of and 8.7% of the patients could not 
have their retina examined.20 Among the 52.7% that had DR, 1.7% had PDR, 63.4% had NPDR 
and 32.2% had diabetic maculopathy. Also, among the 52.7% patients with DR, 55.5% had 
poorly controlled DM, while 44.5% controlled theirs well. More patients on insulin (71.0%) 
developed DR compared to 53.7% patients on oral hypoglycaemic who developed DR. 20  
“Public health strategies to control visual disabilities due to DR include generating 
evidence for planning, implementing standard operating procedures, periodic DR 
screening, focusing on primary prevention of DR, strengthening DR management, health 
information management and retrieval systems for DR, rehabilitating persons that are 
visually disabled from DR, using low-cost technologies, adopting a comprehensive 
approach by integrating DR care into the existing health systems, health 




Eastern Mediterranean Region (EMR) nations prioritized public health approaches to control 
visual impairments due to DR.32   
Although countries of EMR had prioritized public health approaches to tackle visual 
impairments due to DR, inadequate workforce, poor health care and unwillingness of DM 
patients to change their lifestyle all constitute important implementation challenges.32  
DR-related visual impairments and blindness is expected to increase in the near future. There 
is a call for all stakeholders to unite to minimise DR-related visual impairments and blindness.32 
Evidence from studies on planning and developing services for DR in SSA revealed that 
planning for an effective DR screening programme required a health systems approach and 
partnerships with various ministries and professional bodies.33 This study discovered that 
development of DR services should include: “increasing geographical coverage, integration 
into the general healthcare system, and movement from passive, opportunistic services to a 
systematic and proactive service delivery system that is concerned with the prevention of 
DR”.33 It entails that the WHO health systems framework should be used as a tool to 
systematically plan DR services.33   
Kyari et al. (2014) reported that an effective DR program requires the availability of more 
training for retina specialists, the need to provide laser and surgical equipment, availability of 
a system to track patients that needs treatment and follow-up,5 illustrating the need for a holistic 
health systems approach to tackle vision disorders and disabilities due to DR.  
In Oyo state, Nigeria, patients and health care providers reported inadequate health education 
on the effects of DM on the eyes as a significant barrier for seeking diabetic eye services.34 
High cost of DM and DR treatment was identified as a barrier because of user fees and lack of 
health insurance. Long waiting time before consultation due to high patient to provider ratio, 
staff attitudes and lack of empathy towards patients, appointment scheduling strictly based on 
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quota system and missing case files during schedules were all reported by both patients and 
providers as barriers to DR care.34  
“To assess both management of DM and DR in countries and to estimate the level of 
cooperation and synergy between these two branches of health care, The World Health  
Organisation (WHO) has designed the Tool for the assessment of Diabetes and Diabetic  
Retinopathy Management Systems (TADDS)”.2 The tool was designed to be used “to carry out 
situation analysis, define service provision levels, and identify the gaps to be addressed in 
ensuring universal access to DM care and to effective prevention and treatment of DR.2 The 
WHO health systems framework guided the development of this tool into service delivery, 
health workforce, health information management systems, medical products and technologies, 
health financing, leadership and governance”.2  
Despite the rapid increase in the prevalence of DM and DR in AKS,20 and the development of 
the TADDS by WHO to assess DR and DM services for effective and efficient DM and DR 
services,2   no research or situation analysis have been carried out in AKS and Nigeria to assess 
the situation of DR and DM management systems.2 This study is being undertaken using the 
WHO TADDS2.   
2.1     Significance of the study; Increased visual loss from DR in SSA looms from emerging 
DM epidemic. 35 In SSA more research efforts are needed to bridge the evidence gaps related 
to both the “problem” posed by DR (epidemiological evidence and burden of disease across 
population groups) and the “solutions” that could be implemented to prevent avoidable 
blindness due to DR. Many of the solutions are health-systems related and WHO recommended 
for health systems analysis of DM and DR services using WHO TADD 2. This study will 
provide evidence for aspect of DM and DR management systems that need to be prioritized 





3.0             Methodology   
  
3.1               Study design   
  
This was a cross-sectional descriptive case study with the “case” being the prevention and 
management systems of DR in AKS, Nigeria. The decision to do a descriptive case study stems 
from the shortage of current knowledge about DM and DR services in AKS. This study 
involved concurrent use of a questionnaire (WHO TADD) as well as the conduct of semi 
structured interviews. The questionnaire is mostly comprised of close ended questions, 
therefore limiting the possibility of exploring the “how” and “why”. Qualitative interviews 
were used to understand better the barriers and opportunities to improve DM and DR services.  
3.2              Characteristics of study population  
  
The study population included the stakeholders involved in DM management and DR in AKS, 
Nigeria. The stakeholders included representatives of the Ministry of Health (Federal and state 
levels), nurses involved in the care of diabetes, primary care diabetes educators, primary care/ 
family physicians, endocrinologists, diabetologists, ophthalmologists, vitreoretinal specialists, 
and optometrists in AKS.  
3.2.1                          Number of participants  
  
This study included 21 surveys using the WHO “Tool for the assessment of Diabetes and  
Diabetic Retinopathy Management Systems (TADDS)”. In addition, a total of 10 semi 




3.2.2                        Inclusion criteria and exclusion criteria  
  
This research included stakeholders involved in the management/ care of DM and DR. It also 
included the stakeholders involved in policy development of the prevention and control of 
diabetes in AKS and Nigeria.  
This research excluded diabetic patients, stakeholders in private hospitals in AKS and 
stakeholders who refused to give consent.  
3.2.3                      Location of the research   
  
AKS is in the south geopolitical zone of Nigeria. It has the 10th largest land mass in Nigeria, 
covering 7,249 square kilometres. AKS has 31 local government areas (LGA’s). The estimated 
population in 2016 was 5,452, 277. Uyo is the state capital. “The major towns include Eket, 
Ikot Ekpene, Oron, Abak, Itu, Etinan and Ibeno”.36 AKS has a total GDP of $11.179 billion, 
per capita level of $2, 779 36, 37 and poverty rate of 23.8 percent making it the 11th out of the 36 
states in Nigeria in terms of least poverty rate.38 Health facilities are not evenly distributed in 
all the LGA’s but skewed in favour of the urban areas.39   
  
AKS has one (1) federal government owned tertiary hospital, the University of Uyo Teaching 
Hospital (UUTH), under the care of the Federal Ministry of Health serving the entire 
population. UUTH has two (2) endocrinologists, three (3) ophthalmologists, four (4) 
optometrists and four (4) ophthalmic nurses. AKS has forty-three (43) government owned state 
hospitals out of which only three (3) hospitals provide eye care. The entire state-owned general 




 In AKS, between January 2009 and December 2010, the prevalence of DR was 52.7% among 
patients with diabetes aged 19 to 82 years.20 This study by name and al. (year) is one of only 
few studies on diabetic retinopathy in that state.  
The research involved stakeholders from the four hospitals that provide eye care services in  
AKS, that is UUTH, the three-state owned general hospitals (state clinic Uyo, General hospital 
Eket and General Hospital Itu Mbang), as well as from Ministry of Health departments with 
public health responsibilities for the prevention and management of DM and DR.   
Key informant interviews took place in the offices of the stakeholders at UUTH, Federal 
Ministry of Health in Abuja (to have an idea of the national policy on DM and DR), Ministry 
of Health in Uyo (Capital of AKS) and three government owned general hospitals in AKS.   
The questionnaires were administered at the offices of the respondents after obtaining consent.  
  
3.3                 Recruitment and enrolment   
  
For semi-structured interviews: Participants were selected using a purposeful sampling 
approach by enrolling participants directly involved in programmes or services related to DM 
and DR.40   
The embedded researcher, as a health worker who did part of his internship in AKS in 2008, 
has a relationship with some of the stakeholders, so these potential participants were contacted  
first.   
For the key informant interviews, stakeholders were contacted by the embedded researcher in their 
various offices and the aims of the research were explained to them. Stakeholders were given 
recruitment flyers to read and given time to make decisions whether to participate or not in the 
research. Stakeholders who declared their willingness to participate in the research were enrolled, 
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appointments made for convenience and their consent sought before interviews. Stakeholders were 
interviewed until saturation was reached. In qualitative research, the sample size is determined 
when saturation has been reached and new themes stopped emerging from the data. When  
saturation is reached, the researcher stops data collection.40, 41  
  
For the questionnaire (survey):  questionnaire surveys were conducted in the four government 
owned hospitals where services for both DM and DR are available because one of the aims of this 
research is “to explore the existence and the nature of referral pathways between diabetes and 
eye care” and the synergy between DM and DR services. These four hospitals were the only 
hospitals where both DM and DR services are provided, other hospitals do not provide both 
services.  
  
The researcher approached the Head of the department of ophthalmology and internal medicine 
or their equivalent in each of the selected hospitals for approval to distribute recruitment flier 
to the medical and health personnel in these departments. After securing approval from the 
Heads of department, the researcher visited these departments on the clinic days when all the 
medical and health workers were present. The recruitment flyers were shared with the 
personnel. The researcher was available to answer their questions. The recruitment flyers also 
contained the phone number and the contact address of the researcher for clarifications. The 
personnel were given two weeks to make their decision either to participate or not. Personnel 
willing to participate were recruited and issued with the questionnaires after consent was 
obtained.   
  
3.4              Research procedure and data collection methods  
  
Key informant interviews were conducted face to face as was preferred by all the participants.  
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Face to face interviews took place at the offices of the key informants or any other private room 
suggested by the key informant without a third-party present, to maintain privacy and 
confidentiality. Key informant interviews were recorded with a tape recorder for transcription 
after securing consent from the respondents. The interview lasted an hour on average for each 
participant.  
The questionnaires were administered face to face in private rooms without a third party. The 
participants were asked not to write their names or any information that could be linked to them 
in the questionnaire to maintain privacy and confidentiality. Each questionnaire was assigned 
a unique code by the researcher. The questionnaire was completed in about one hour.  
3.5                Data safety and monitoring plan   
  
As mentioned, each questionnaire was given a unique code and the data extraction was carried 
out by the researcher alone. The recorded interviews were cross-checked and kept under lock 
and key. The data was stored in a password protected computer and backed up on a password 
protected compact disc plate. Only the researcher had access to the data. After analysis, the 
data was stored in the computer and will be deleted permanently.  
3.6               Data analysis  
  
3.6.1               Research instrument     
  
The research instrument for this research is the WHO TADDS2 and interview guide (see 
appendix). The interview guide has the same themes as the WHO TADDS.2  
  




According to the WHO, “Development of the TADDS was coordinated by the World Health 
Organization, Prevention of Blindness and Deafness, and technically supported by the Centre 
for Eye Research Australia (University of Melbourne) and the Menzies Centre for Health 
Policy (University of Sydney). The International Council of Ophthalmology provided technical 
comments throughout.2 The research instrument was also field tested for validity and 
reliability”.2 The semi structured interview was conducted using an interview guide. The 
interview guide was developed under the same themes as the TADDS. The researcher piloted 
the interview guide by interviewing some ophthalmologists outside AKS to validate the 
interview guide before the actual research in AKS. 
3.6.3          Plan for data analysis   
  
KI interviews were recorded after obtaining consent from participants or handwritten if a 
participant refused to be voice recorded. Each interview was transcribed verbatim and, as 
recommended by WHO, coded thematically based on the WHO TADDS2 dimensions of DM 
and DR systems.  
Descriptive statistics - frequency and percentages - were used to summarise quantitative data 
under the themes used in the TADDS using Stata 14 software.  
  
4.0          Ethics considerations  
  
Ethical approval from University of Cape Town Human Research Ethics Committee (HREC), 
University of Uyo Teaching Hospital (UUTH) ethics committee and the ethics committee of 
the Ministry of Health in AKS will be obtained before proceeding with the research.  




This study does not pose a physical risk or medical risk to the participants. However, the 
participant might face the risk of being sanctioned for giving out sensitive information 
concerning understaffing/ lack of staff, inadequate/lack of infrastructures or ineffective health 
systems generally which are mostly political issues in Nigeria. However, this risk was 
eliminated through conducting interviews in private rooms without a third party and coding 
data such that it cannot be linked to the participants. Information that can reveal individual 
identities like names, age is not required in the survey.   
There might not be direct individual benefits for the participants. However, this research will 
benefit the health system generally through the recognition of the gaps that should be filled for 
effective holistic management of DM and DR. The findings from this research will also be used 
to advocate for more attention in the prevention, management and care of DM and DR in AKS. 
The findings from this research can also be used to inform policy that will tackle the increasing 
rate of DM and DR. Other researchers will also benefit from the findings from the research for 
further researches.   
6.0          Informed consent  
  
The purpose and objectives of this research were explained to the participants. The participants 
were informed that participating in this research was voluntary and that they had the right to 
discontinue their participation in this research at any time. They also had right not to answer 
any question that they were not comfortable with.  
The participants were given reasonable time to decide if they were willing to participate in this 
research or not.  
The participants signed consent forms before participating in this research.  
For telephone and internet-based interviews, participants were required to give verbal consent.  
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No information was withheld from participants concerning this research.  
7.0        Privacy and confidentiality   
  
Interviews and surveys were carried out at the respondents’ convenient time. Interviews and 
surveys took place in private rooms without a third party. Personal identifiable details were 
collected during the interviews and surveys. Data has been coded by the researcher. The 
research data, electronic and hard copy, was stored in a password protected computer and under 
lock and key respectively. Only the researcher has access to the data. At the end of the research, 
hardcopy data will be burnt while data in the computer will be wiped permanently.    
8.0       Reimbursement for participation  
  
Participants were informed that there was no financial compensation for participating in this 
research.  
9.0       Dissemination of study   
  
The participants were informed that the results from this research will be presented in 
conferences and seminars. The findings from this study will be provided to policy makers in 
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Specific objectives of the literature review  
The specific objectives of this literature review are:  
1) To review the scientific evidence (clinical overview) on the aetiology, known risk 
factors and prevention of DR;   
2) To review the epidemiological data on DM and DR globally and in sub-Saharan Africa 
(SSA), and  
3) To review the evidence on effectiveness and cost-effectiveness of public health and 
health systems interventions for the prevention and management of DR.   
Search strategy   
For the first and second objectives of the literature review, we present only an overview of the 
available evidence. There is a greater emphasis on the third objective on effective interventions, 
as it is more centrally aligned with the main objective of this dissertation and the content of the 
WHO TADDS (health systems readiness).   
Databases: The following databases were searched: PubMed, Science, web of science, 
ProQuest, Cochrane library, google scholar and grey literatures through Google and medical 
websites.   
We used general search terms with the Boolean operator “AND” in PubMed and google scholar 
for objectives 1 and 2 – using “diabetic retinopathy” AND the following terms in succession - 
“risk factors”, “epidemiology”, “Nigeria” and “sub-Saharan Africa.”  
For the search on public health and health systems interventions, we used the following strategy 
with index and subject terms:   
Keywords: ("methods"[Subheading] OR "methods"[All Fields] OR "methods"[MeSH                
Terms]) AND ("methods"[MeSH Terms] OR "methods"[All Fields] OR "intervention"[All  
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Fields]) AND ("diabetic retinopathy"[MeSH Terms] OR ("diabetic"[All Fields] AND 
"retinopathy"[All Fields]) OR "diabetic retinopathy"[All Fields]) AND services [All Fields].  
Inclusion: All study designs, summaries, reports and articles that reported relevant DR 
interventions associated with effective outcomes. There was no year restriction.  
Exclusion: Studies that merely proposed or recommended interventions without proven 
effective outcomes were excluded in this review. Studies with only abstract but no full text, 
studies published in languages other than English.  
Results: fifty-nine articles (53 journal articles, 3 reports and 3 website articles) on features of 
intervention with better outcome on DR management challenges were reviewed out of the of 














Literature review  
Diabetic Retinopathy: Clinical overview  
Diabetic retinopathy (DR) is a diabetes-related structural and functional damage to the retina 
caused by persistently abnormal blood sugar levels damaging blood vessels that supply the 
retina.1 DR develops in patients with both type 1 (T1DM) and type 2 (T2DM) diabetes who 
have suffered from the disease for a long time.2 DR is a secondary microvascular complication 
of DM and can cause blindness if left undiagnosed and untreated.3 It starts with retinal 
nonperfusion and ischemia resulting from the closure of blood vessels.4 DR can be non-
proliferative (NPDR) or proliferative (PDR).5  
NPDR is the early stage of DR characterized by tiny blood vessels leak, which makes the retina 
swell.4-7 Retinal non-perfusion and ischaemia result from the closure of the blood vessels.4 
PDR happens when retinal ischaemia is sufficiently severe causing the retina to start growing 
new blood vessels (neovascularization). These fragile new vessels might bleed into the 
vitreous, causing floaters or complete loss of vision.7 PDR can lead to both central and 
peripheral (side) vision loss.6 50% of patients with PDR could become blind within 5 years 
without treatment.8  
Risk factors  
Numerous risk factors of DR have been investigated and identified in epidemiological studies 
and clinical trials, as summarised below:  
Hypertension: Elevated blood pressure is a major risk factor for the development of DR.9-16 
Klein et al. (1995), in their study to determine whether blood pressure at baseline was 
associated with incidence or progression of DR during a 10-year interval in a population-based 
cohort, reported that increased systolic blood pressure at baseline was associated with increased 
risk of incidence of DR in subjects with younger-onset diabetes (odds ratio, 1.27; 95% cl, 1.03 
6  
  
to 1.57).17 Similarly, in a large cohort study conducted in Germany by Hammes et al.(2011), 
among patients with TIDM, elevated blood pressure (>140/90 mmHg) was reported as a risk  
While some studies reported elevated  
systolic blood pressure as the risk factor for DR,10-14 other studies on the contrary reported 
elevated diastolic pressure as the risk factor for DR.15, 16   
Age and Sex:  Zou et al. (2016) reported that onset of diabetes at age of 31–45 years was linked 
with increased risk of developing DR; however, the causal mechanism remains unclear.18 
Stratton et al. (2001) reported that the older the age among diabetics, the higher the likelihood 
to develop DR.19 A study by Zhang et al, (2010) showed that among US adults with diabetes 
aged 40 years and older, older age among the males was reported as a risk factor,10 also, 
Hammes et al. (2011) reported male sex as a risk factor for DR.9  
High Haemoglobin A1C Level and Hyperglycaemia: The systematic review and  
metanalysis by Song et al. (2018) reported higher HbA1c as a risk factor for DR (OR=1.15 
(95% CI = 1.09-1.20) in China.20 Yau et al. (2012) reported that prevalence of DR among those 
with HbA1c of 7 or less was 18% and 51.2% among those with HbA1c of greater than nine.21 
High HbA1c has been reported as a risk factor for DR in various studies.10, 12, 15 Van et al.  
(2003) reported an association between hyperglycaemia and the incidence of DR (OR 3.29 
(95% CI, 1.11-9.72)) in the Hoorn study.22  
Insulin use: In the systematic review and metanalysis of risk factors of DR in China, Song et 
al. (2018) reported that insulin use was significantly associated with DR (OR=1.99, 95% 
CI = 1.34-2.95).20 Similarly, in the systematic review and metanalysis of BMI and DR, Zhou 
et al. (2017) reported an association between insulin use (OR=2.64, 95% CI: 1.50-4.64, 
p=0.001) and DR.23 However, other studies gave inconsistent associations between insulin and  
DR.13, 19, 24   




Dyslipidaemia: In a systematic review and metanalysis to evaluate the association between 
triglycerides (TG), serum total cholesterol (TC), high-density lipoprotein cholesterol (HDLC), 
low-density lipoprotein cholesterol (LDL-C) and DR, Zhou et al. (2018) reported slightly 
higher LDL-C levels in DR cases (MD 3.74  mg/dL, 95% CI: 0.13–7.35, P = .04) compared to 
controls.25 Also, Shi et al. (2018) reported that lipid-lowering medications were associated with 
reduced risk in DR progression [OR=0.77 (95% CI: 0.62, 0.96), P=0.02].26  
Body mass index (BMI):  the meta-analysis conducted by Zhu et al. (2018) showed an 
association between obesity and high incidence of DR (relative risk [RR], 1.20; 95% 
confidence interval [CI], 1.01–1.43; I 2 = 59.6%). However, the study found no association 
between obesity and PDR but a harmful association between obesity and T2DM (RR, 1.40; 
95% CI, 1.05–1.87; I 2= 67.6%). However, it found no harmful association between BMI and 
the mixed group (RR, 1.04; 95% CI, 0.97–1.18; I 2 = 0.00%). The study concluded that “obesity 
was a risk factor for NPDR”.27  
Duration of DM: Systematic review by Yau et al. (2012) reported that globally 21.1% of those 
with DM duration of less than ten years develop DR compared to 76.3% for those with DM 
duration of twenty years and above.21 Studies have shown that diabetic patients after 10 years 
of disease with poor glycaemic control have a higher risk of DR28 and patients with poor 
glycaemic control are more likely to develop DR with higher risks in 11–15 years of disease 
and greater than 15 years.28 So, there is a recommendation for proper and adequate glycaemic 
control to minimise DR.19  
Epidemiology of DR in Africa  
DR is a leading cause of preventable vision loss globally29 and the leading cause of vision loss 
in adults (20-65 years).30 In 2010, it was estimated that one third of the estimated 285 million 
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people with DM worldwide have signs of DR.21 It is estimated that 21% – 25% of individuals 
with type 2 diabetes mellitus have DR at diagnosis of diabetes and, overall, DR affects 15% - 
55% of all DM cases at diagnosis.31  
In SSA, few data on the prevalence of DR have been published.32 The International Diabetes 
Federation (IDF) however estimated that the number of adults with DM in Africa will increase 
from 12.1 million in 2010 to 23.9 million in 2030.33 Almost all the 48 resource-poor countries, 
as defined by the United Nations (UN), are in Africa.34 Therefore, the epidemic rise in diabetes 
poses important public health and socioeconomic challenges for Africa.7  
According to the systematic review of sixty‐two studies from 21 African countries by Burgess 
et al. (2013), the prevalence estimates of DR in patients with DM ranged from 30.2% to 31.6%, 
for PDR from 0.9% to 1.3%, and for any maculopathy from 1.2% to 4.5% in population‐based 
studies. In diabetes clinic‐based surveys, the prevalence estimates of DR ranged from 7.0% to 
62.4%, for PDR from 0% to 6.9%, and for any maculopathy from 1.2% to 31.1%.7   
Burgess et al. (2017), in a study among people with over 5 years diabetes in Southern Malawi, 
reported that the incidence of ≥ 2 step retinopathy progression was 36.4%; (95% CI: 28.2– 
44.6). The incidence of sight threatening diabetic retinopathy (STDR) for those with level 10  
(no retinopathy) at baseline was 19.4% (95% Cl 11.3–27.4) while for those with level 20 
(background) retinopathy at baseline it was 81.3% (95% Cl 62.1–100).35   
In 2011, Glover et al. (2012) reported that in Malawi, the prevalence of any retinopathy among 
people with TIDM was 28.1%, STDR was 18.8% and PDR was 12.5%, while among patients 




According to the national survey of visual impairment in Botswana 2007, DR was the second 
leading cause of blindness after cataract among people aged 50 years and older, with a 
prevalence of 20%.36   
In Nigeria, the national Blindness and Visual Impairment Survey (2005 - 2007) among adults 
aged ≥ 40 years revealed that DR contributed to 0.29% of the total causes of blindness and 
visual impairment.37   
A study by Bogunjoko (2016) reported that among the estimated population of 740,000 above 
the age of forty (40) in Ogun State of Nigeria in 2015, 3.3% had DM. Among those with DM, 
17% of all DM had DR, 12% of DR cases had sight threatening DR.38  
In Akwa Ibom State (AKS), Nigeria, between January 2009 and December 2010, a study of 
patients with DM aged 19 to 82 years revealed that 94.5% of the patients had T2DM, 4.6% had 
T1DM and 0.9% had gestational DM. The prevalence of DR was 52.7% among the examined 
patients.39 Among the 52.7% that had DR, 1.7% had PDR, 63.4% had NPDR and 32.2% had 
diabetic maculopathy.39  
In 2017, Abraham and Megbelayin (2017) reported that DR was the second commonest 
posterior segment disease (2.0%) after age related macular degeneration (AMD) (37.5%) 
among 547 participants of free eye screening programs in Uyo, AKS, Nigeria with age ranging 
from one (1) to eighty-seven (87) years. This study concluded that the eye health awareness 
and eye health indices of AKS is still very poor.40 This entails the need for gap analysis and 






The prevalence of DR in some countries in SSA is summarised in the table below: 
Table 1: Diabetic retinopathy prevalence estimates from published studies in Africa. 
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Health systems challenges for the prevention and management of DR  
Studies have reported health systems challenges faced by DR systems globally. The systematic 
review by Graham‐Rowe et al. (2018) identified lack of access to DR services in the rural areas, 
poverty, ignorance of DR by diabetics, beliefs about consequences of DR, lack of support to 
people with diabetes. They concluded that the major barriers within these groups included: 
erroneous diabetic registers and misunderstanding by patients and providers between routine 
eye care and retinopathy screening.56   
Other studies also reported similar challenges, but with added factors, which include: lack of 
knowledge about DR by the patient,57lack/inadequate eye care infrastructure and human 
resources, lack of systems to trace patients for follow up,58 limited access to ophthalmic 
services,59lack of guidelines for DR services, lack/inadequate staff training, insufficient referral 
of patients, lack of retinal treatment, cost of DR services,60 confusion between health workers, 
pain and visual disturbances after mydriasis,61 difficulty with the integration of DR screening 
with other care, paying more attention to the newly diagnosed by the health workers  
managing DR,62 lack of knowledge of the management of DR (except from the  
ophthalmologists and endocrinologists),63 and language barrier.64  
In Nigeria, DR system challenges include: family-related barriers, community and societal 
influence, use of traditional medications from herbalists, inability of patients to pay for DR 
services, lack of health insurance, transport and distance to specialists clinics, lack of escorts 
to clinic, long waiting time in the clinic, inconvenient appointment scheduling, harsh and 
disrespectful behaviours by health workers towards DR patients, lack/inadequate equipment, 




With these challenges, visual challenges due to DR are likely to increase in the coming years. 
Experts have called for the adoption of a public health approach for all stakeholders to work 
together for interventions that will put severe visual disabilities due to DR under control.66  
Features of interventions associated with better DR outcomes   
Based on studies and programmes in Latin America, von-Bischhoffshausen and al. (2011) 
highlighted that  a programme to manage DR services should include the following: proper 
understanding of the present and expected prevalence of DR (to make it possible to plan 
services for prevention, screening and treatment), the existence of clinical guidelines and 
effective  ways of discovering patients with DM and DR, screening and retinal examination 
methods that maximize the equipment and personnel available, availability of laser treatment 
centres for appropriate treatment, health promotion and prevention programmes that reach the 
whole population, advocacy to obtain the backing and support of the authorities and 
stakeholders, and lasting sustainability using cost recovery or subsidies.67  
A similar study in Africa by Poore et al. (2015) revealed that planning for an effective, 
sustainable and integrated DR screening programme required a health systems approach and 
partnerships with various ministries and professional bodies. This study reported that the 
development of DR services should include: integration into the general healthcare system and 
changing from opportunistic services in the clinic to a regular and proactive service delivery 
system that is centred on the prevention of DR.68 The study suggests that a comprehensive 
health system approach is necessary to systematically plan for DR prevention and treatment 
services.  
In this section, we adopt a health systems approach to present the results of the literature review 
related to health systems and health policy interventions for the prevention and management 
of DR.   
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This section reviewed studies that reported interventions associated with better outcomes. 
Studies that proposed or recommended interventions without outcomes were excluded from 
this review. However, results from our search showed a paucity of studies on DR interventions 
in Africa.  
Service Delivery: Systematic reviews have examined the effectiveness of DR screening 
intervals.69, 70 Echouffo-Tcheugui et al. (2013) reported that it is safe and effective to conduct 
screening for patients with DM but without DR biannually, except for individuals with poor 
glycaemic control or uncontrolled hypertension.69 The systematic review by Taylor-Phillips et 
al. (2015) found similar results.70 However, they reported that available evidence is not 
sufficient to extend screening intervals past 1 year because of the lack of experimental research 
design and differences in the definition of those who are at low risk in the different studies.70  
The systematic review by Lawrenson et al. (2018) reported that Behavioural Change  
Techniques (BCT’s) improved the DR screening attendance by 12% compared to usual care.71 
The techniques investigated were: “the use of  feedback mechanism, proper and effective 
information on the screening methods and processes, the use of credible sources in the society 
to provide information to the patients, the use of reminder systems, the use of national 
guidelines, improved patients convenience and screening environment via online 
management/booking systems or monitoring tools such as diabetes passports”.71    
In developed clime of  Europe, America and part of Asia,   service delivery interventions such 
as: tracing DM patients through phone calls,72 recruitment strategies (like target mail outs, 
printing of program pamphlets, creating awareness in the mass media in ethnic language,73 the 
use of checklist based intervention for screening of DM complications by health personnel74 
and use of the reminder system to remind patients of their periodic diabetic retinal 
examination75 improved DR screening uptake, compliance and services.  
15  
  
Telephone intervention was reported to effectively improve participation in DR screening.76 
Walker et al (2008) reported in a randomised controlled trial that the use of a telephone 
intervention to promote retinopathy screening increased DR screening by 74% compared to a 
standard print intervention in three health centres in the Bronx in New York. This study also 
reported that patients who previously had poor control of diabetes responded with greater 
success to telephone interventions than standard print intervention.76  
In sub-Saharan Africa, partnership and joint eye and DM services based in the eye department 
promoted effective routine referral of DM patients to have their eyes examined in Tanzania 
and Ghana.53 Similarly, in two clinics in Botswana, joint services based in the eye department 
resulted in provision of consistent weekly service and stable arrangement of patient movement 
between the eye and diabetes departments.68    
However, outreach / field DR screening intervention based at patients’ local clinic was 
effective   in the diabetes programs in Kilimanjaro in Tanzania and in the Copperbelt province 
in Zambia. The programs recorded high screening rates, with a Kilimanjaro diabetic program 
(KDP) screening rate of 90% among 3,175 registered DM patients within two months, while 
in the Copperbelt programme screened 1,233 patients within five months. The Copperbelt 
programme  though faced with the lack of systems to facilitate call/recall (poor mobile phone coverage, 
poor literacy, lack of postal systems, lack of diabetic registers), demonstrated that the   Provision of 
information and education to the diabetic clinics and community was effective in inviting 
people for screening in the local clinics in Copperbelt, indicating that services can still thrive 
where resources are not available to start registers and formal call/recall systems.68 However, 
comparative cost analysis was not included. 
Cost/financial intervention: A systematic review by Jones and Edward (2010) reported that 
DR screening programmes are cost-effective interventions in high-income countries. However, 
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this has not been determined in African settings.77 In the developed countries, structured 
systematic screening program that targets the population has been reported to be cost-effective  
when compared to opportunistic screening which targets only few patients.78-81  
A systematic review by Pasquel et al. (2016) reported that telemedicine lessens the burden on 
the eye clinic, improves access in the inaccessible communities and is cost effective in relation 
to clinical practice.82 This finding is consistent with that of a systematic review by Jones and 
Edward (2010)77 and other studies.83-85  
In SSA, teleophthalmology screenings involving the use of digital non-mydriatic fundus 
photography to capture retinal images by non-ophthalmologist in primary health care setting 
and images interpreted by experienced medical officer has been reported to be very cost-
effective in South Africa.86  
Early incorporation of DR into the main national diabetes program in the planning phase 
increases the chances of donor funding of DR in SSA.53 DR programmes in Tanzania involving 
the Muhimbili Hospital in Dar es Salaam and the KDP Tanzania showed that collaborations 
with the Tanzania Diabetic Association resulted in the inclusion of DR in the overall diabetes 
scheme and easier network with diabetic funding bodies.68  
Free DR screening in SSA is reported to have increased the compliance of eye screening among 
patients with DM.87 In Tanzania, a free examination as an intervention increased attendance 
from about 20% to 47% of those who had not been examined before this intervention among 
diabetics over the age of 18 attending the diabetic clinic at Kilimanjaro Christian Medical 
Centre (KCMC).87  
Infrastructure/technology and Human Resources: Telemedicine has proven to be an 
effective technological intervention for DR programmes and management systems.88  
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A systematic review by Shi et al. (2015) reported that teleretinal examination has sensitivity 
greater than 80% in detecting the absence of DR, pooled specificity of greater than 90%, the 
use of wider angle image of 100 to 200 degrees and use of mydriatic agents increases accuracy 
in various clinical levels of DR and DME.88 Similarly, Tozer et al (2015) reported high clinical 
accuracy of telemedicine in the screening of DR in the developed countries, and globally. They 
concluded that telemedicine has been implemented successfully across the globe.89  
Similarly, in SSA, Blanckenberg et al. (2011) reported the use of a handheld ophthalmoscope 
that combines a digital camera to capture retinal images. The images captured are transferred 
to a mobile phone and then sent to a central website for evaluation. The evaluation report is 
automatically returned to the mobile phone via SMS. The quality of the images was rated as 
acceptable for clinical use by medical specialists at the Department of Ophthalmology of the  
Health Sciences Faculty of Stellenbosch University, South Africa.90  
 
However, Poore et al. (2015) reported that in five DR screening services in Botswana, Ghana, 
Tanzania (with two sites) and Zambia using fundus cameras, four out of the five programmes 
had setbacks of malfunctioning cameras. They recommended negotiations with suppliers on 
machine maintenance and training of staff before purchase.68  
Considering human resources, training of non-ophthalmologists such as optometrists and 
general physicians to carry out screening of DR were reported to be effective and showed a 
good rate of agreement with the diagnoses made by the ophthalmologists in different climes.91, 
92 In SSA, Poore et al. (2015) reported that adequate training for non-ophthalmologists provides 
them with the competency to screen and grade DR due to the scarcity of ophthalmologists in 
SSA.68  
Poore et al. (2015) reported interventions on workforce sustainability to include: training 
personnel on permanent employment in the eye unit, providing DR services in the facilities, 
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arrangements with the Ministry of Health (MOH) to keep providers of DR services constant in 
the eye unit to curb the challenge of staff transfer, open curriculum to meet demands of the 
epidemic of DM by healthcare professionals, licensing and recognising of the new roles of 
health workers involved in task shifting.68 In Ghana, ophthalmic nurses were trained to use slit 
lamp after approval was obtained from the Nursing and Midwifery Council of Ghana.68 Also, 
in Tanzanian national eye care plan, the MOH included ophthalmic equipment maintenance in 
the curriculum of undergraduates.93  
Leadership and governance: Leadership intervention that involved the engagement of 
various stakeholders in the Pakistan diabetic program, via the national diabetic task force, 
resulted in intense advocacy with evidence on the need for DR services in Pakistan, forcing 
government to include DR services in the budget and the development of guideline on DR 
treatment with laser and avastin.94 Similar results were reported by Jiao et al. (2016)95 and  
Shaw et al. (2010).96  
 
In SSA, Poore et al. (2015) reported that multidisciplinary planning and management involving 
endocrinologist, programme manager, database designer and ophthalmologists on the 
management committee in KDP promoted interdepartmental relationships and enabled 
linkages with other general/diabetic doctors in the region, national diabetes networks and 
international funding bodies.68 The inclusion of MOH in DR screening services, high-level 
stakeholders’ engagements in planning the national programme, availability of national eye 
care plan and good leadership were responsible for the sustenance of DR services in Botswana, 
Ghana, Tanzania and Zambia.68 These strategies can be utilized to close the leadership gap in 
the planning and execution of DR programmes.  
Medical products: The availability of quality medical products is a crucial factor towards the 
effectiveness of a DR programme.68 According to the American Academy of Ophthalmology, 
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treatment strategies for DR to prevent severe vision loss is effective in 90% of DR cases. The 
treatment options are laser therapy, anti-VEGF (anti-vascular endothelial growth factor) drugs 
(bevacizumab, ranibizumab, aflibercept) and surgery.  
The introduction of intravitreal injections such as anti-VEGF for DR has had a huge influence 
on the DR treatment paradigm worldwide. Intravitreal injection of anti-VEGF agent has now 
become the principal treatment modality for diabetic macular oedema.97-100 According to the 
DR Clinical Research Network (DRCR), anti-VEGF therapy for DME results to lasting vision 
improvements compared to laser or combination treatments.99  
However, the United Kingdom Proliferative DR study (DCCT-UKPDS) reported that the 
crucial factor in therapeutic management of DR is effective glycaemic control, which will 
result to reduction in the risk of diagnosing new cases of DR and reduction in the progression 
of existing DR.  
In Africa, given the current difficulty in providing costly therapeutic interventions, a well-
planned, cost-effective prevention strategy is required.101  
The International Diabetes Federation (IDF), Africa Region, initiated the African Diabetes 
Declaration,102 that required the governments, non-governmental organisations (NGOs) and 
stakeholders to guarantee availability of inexpensive medications.103 Novo Nordisk (a 
multinational pharmaceutical company) introduced equity pricing initiative in the 50 poorest 
countries by supplying insulin at prices not higher than 20% of average prices in developed 
countries.104 This intervention crashed the price of insulin in the public sector in Mozambique 
by 50%. Novo Nordisk through World Diabetes Foundation provided grants to support 
prevention and treatment of diabetes in Tanzania, collaborating with the Tanzanian Diabetes 
Association and Ministry of Health to establish a system of diabetes clinics throughout the 
country, provide health-workers training, guidelines, and patient education material.105  
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The IDF team through its “twinning initiative”106 inspired IDF member associations in 
developed countries to partner with associations in developing nation to aid them.103 This 
initiative resulted in support from diabetes UK to diabetes Mozambique and support from 
Norwegian Diabetes Association to Zambia.103   
Africa is faced with numerous DR systems challenges with little interventions to combat these 
challenges.68 These gaps are contextually peculiar to each DR management system hence the 
need for contextual interventions.68 The first step will be to carry out a situational analysis in 
each setting to assess the gaps and needs that exists in such DR systems before interventions.107 
No known study of situational analysis of DR system has been carried out in Akwa Ibom State, 
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 ABSTRACT  
  
Purpose: To investigate and analyse the situation of diabetic mellitus (DM) and diabetic 
retinopathy (DR) services in government hospitals in the Akwa Ibom State (AKS) in Nigeria.    
Methods: We conducted a descriptive case study using the WHO “Tool for the Assessment of  
Diabetes Retinopathy and Diabetes Management Systems” (TADDS) to survey health 
personnel involved in the management of DM and DR in government hospitals in  
AKS. Concurrently, semi-structured interviews were conducted with ten (10) key informants. 
Qualitative data from transcribed interviews and quantitative data from the TADDS survey 
were triangulated and thematically analysed under the WHO health systems framework.  
Results: The main gaps identified included: low priority of DM and DR in the National Health 
Agenda; lack of policies and programmes for DM and DR; lack of consensus about clinical 
management guidelines for DM and DR; lack of reciprocal referrals between providers of DM 
and DR services; the lack of follow up systems of patients with DM and DR; inadequate health 
workforce; lack of training for health workforce; lack of modern technology for DM and DR 
care; lack of consensus on DM and DR indicators to be monitored; and  proportionately high 
out of pocket payments for DM and DR services.  
Conclusion: Findings reveal that several components of the health system need to be 
strengthened to better serve patients with DR in AKS. The present situation of DM and DR 
services in AKS requires advocacy by the stakeholders for prioritization of DM and DR by the 
government, decentralization of DR and DM services to the primary level, employment of more 
specialists and training of other health workers on how to screen for DR, provision of the 
modern technologies for DR and DM, and more importantly, formulation of guidelines for DR 
and DM management  by all stakeholders. 
4  
  
INTRODUCTION.   
  
Diabetes mellitus (DM) has become a major public health problem.1, 2 Presently, it is estimated 
that about 500 million people live with diabetes, 425 million of those people are between the 
ages of 20 to 79.3 About 80% of the global diabetes burden is in low and middle-income 
countries.4, 5 By 2036,6 the number of people with DM is estimated at 529 million, and at 629 
million by 2045.7   
In sub-Saharan Africa (SSA), the number of people living with DM was estimated to be 19.8 
million in 2013 and by 2035, it is projected that this number will increase to 41.4 million 
(+109%)6, but public health strategies required for the management of the emerging epidemics 
of DM are insufficient or not existing at all.6  
In 2014, Nigeria was estimated to have 4 million diabetes patients, a fifth of all cases of DM 
in SSA.7 However, 70% - 80% of all cases were either undiagnosed or untreated.7 This resulted 
in many patients presenting to the secondary and tertiary health care centres with the disease 
at an advanced stage.8 “Poverty, lack of awareness about the disease, attribution of symptoms 
to myths, lack or inadequate tools and basic infrastructure and inadequate training of health 
workers are the factors responsible for most of the failures to detect DM and for the increased 
risk of misdiagnosis and late diagnosis of patients at complication stages of the disease”.9  
DR results from the damage caused by diabetes to the blood vessels in the retina. Diabetic 
retinopathy occurs when the small blood vessels in the retina leak blood and other fluids.10 DR 
is a progressive condition and is potentially vision threatening.11 It is the commonest and 
potentially most blinding of all ophthalmic complications from diabetes.12-14   
Globally, DR accounts for 5% of all blindness.15 It is one of the  leading causes of blindness in 
people aged 15 – 64 years in developed countries.16 DR is now an important cause of blindness 
in the developing countries with the near pandemic situation of DM in the world.5  
5  
  
Findings from the national blindness and visual impairment (VI) survey in Nigeria between 
2005 and 2007 showed that the of DR contributed 0.29% of VI (Visual acuity of less than 6/12)   
and 0.5% of all blindness (Visual acuity below 3/60).17 However, Burgess et al. (2013), 
reported that the survey was focused more on treatable causes of VI were over preventable 
causes hence the likelihood of underreporting the contribution of DR.18  
The prevalence of DR in DM patients aged 19 to 82 years in Akwa-Ibom State (AKS), Nigeria, 
between January 2009 and December 2010 was estimated to be 52.7%.19  
Visual disabilities from DR are likely to increase in the coming years. An organized public 
health approach involving all stakeholders is required to prevent and control visual disabilities 
due to DR.20  
The multidisciplinary needs of DM and DR patients over a lifetime is a challenge for health 
providers because it affects all fundamentals of health systems: leadership and governance, 
service delivery, workforce, facilities, technology and pharmaceuticals.21  
The World Health Organisation (WHO) has developed a tool for the assessment of DR and 
DM management systems (TADDS),2 guided by the WHO health systems framework to enable 
countries to carry out a situation analysis, define service provision levels, and identify the gaps 
to be strengthened to curb the catastrophic trend of DM and DR epidemics.2  
No research or situation analysis have been carried out in Akwa Ibom State and Nigeria to 
assess the situation of DR and DM management systems despite the estimated high prevalence 
of DR in this state.   
6  
  
The purpose of this study was to investigate and analyse the situation of DM and DR services 
in government hospitals in AKS, Nigeria using a systematic approach guided by the WHO 
TADDS.   
MATERIALS AND METHODS  
  
This study is a cross sectional descriptive case study, with the “case” being the prevention and 
management systems of DM and DR in Akwa Ibom State (AKS), Nigeria. The study 
participants were recruited using purposeful sampling strategy. The study involved 
stakeholders directly involved in programmes or services related to diabetes and DR from the 
four (4) government hospitals in AKS where DM and eye services are provided (University of 
Uyo teaching hospital, State Clinic Uyo, General hospitals in Eket and Ituk Mbang) as well as 
from Ministry of Health (MOH) departments with public health responsibilities for the 
prevention and management of DM and DR.   
The study involved concurrent use of semi-structured key informant interview and 
questionnaire (WHO TADDS) administered to DM and DR stakeholders.   
For the questionnaire (survey), the Heads of departments of ophthalmology and internal 
medicine or its equivalent in each of the selected hospitals approved the distribution of 
recruitment flyer to health providers in these departments. The researcher was available to 
answer their questions. The recruitment flyer also had the phone number and the contact 
address of the researcher for clarifications. The providers were given adequate time (2 weeks) 
to make their decision either to participate or not. Twenty-one (21) health providers involved 
in the management of DM and DR in these four (4) hospitals were willing to participate in the 
research out of twenty-three (23). They were recruited and were issued with the questionnaires 
after consents were obtained. All participants were administered hard copies of the 
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questionnaires without identifiers. Questionnaires were filled maintaining confidentialities. 
Filling of each questionnaire by the respondents took about one (1) hour.   
For the key informant interviews, stakeholders were contacted by the researcher in their various 
offices and the aims of the research were explained to them. Stakeholders were given 
recruitment flyers to read. They were given time to decide whether to participate in the research 
or not. Stakeholders who declared their willingness to participate in the research were enrolled, 
appointments were made, and their consent sought before interviews. The researcher 
interviewed all the stakeholders at their convenient times, in private rooms without third 
parties. All the interviews were conducted face to face and in English. Five (5) interviews were 
recorded with a voice recorder after obtaining permission from the participants, while five (5) 
were hand written after the participants declined voice recording. The interviews were semi 
structured, and the researcher used an interview guide that included the same themes as the 
WHO TADDS. Each interview lasted one hour on average. The process of conducting 
interviews stopped when data saturation was reached, in this case after ten (10) interviews.22, 
23,  Each interview was transcribed verbatim and, as recommended by WHO, coded 
thematically based on the WHO TADDS dimensions of DM and DR systems.    
For the questionnaire, the data was inputted into Microsoft Excel 2010, then a database 
codebook was created to assist in analysis. The accuracy of the data entry from the 
questionnaire responses was checked manually and when an error was identified, extra 
checking and corrections were made by the researcher.  
Data was then transferred to statistics and data software, Stata 14 for further analysis.  
The quantitative data analysis was descriptive. The statistics were mainly frequencies and 
percentages (proportion). These statistics were summarized under each individual section 
/category used in the TADDS.  
Ethical approval was obtained from the University of Cape Town Human and Ethics  
8  
  
Committee, University of Uyo Teaching Hospital Ethical Committee and the Akwa Ibom State  
MOH Ethics Committee.   
Participants signed informed consent forms before participating in interviews and surveys     
                      
                               RESULTS    
 
Among the 10 (ten) stakeholders interviewed, there were: 2 (20%) endocrinologists, 3 (30%) 
ophthalmologists and 2 (20%) Ministry of Health directors (see Table 1.0).  Twenty-three (23) 
questionnaires were sent out while twenty-one (21) (91.30%) were returned. The other two (2) (8.70%) 
could not be reached.  
  
Table 1.0 Key informants and questionnaire respondents on DR and DM services.   
  
Category  Frequency/ percentage  
Semi-structured interviews  
Frequency/percentage  
TADDS Questionnaire  
Endocrinologist  2 (20.0%)  1 (4.8%)  
Medical officer  2 (20.0%)  6 (28.6%)  
Ophthalmologist  3 (30.0%)  4 (19.0%)  
Optometrist  1 (10.0%)  6 (28.6%)  
Director from the Ministry 
of Health  
2 (20,0%)  4 (19.0%)  









PRIORITIES, POLICIES AND PROGRAMMES  
  
National Diabetes Plan or Programme  
  
Among the 21 questionnaire respondents, 71.5% reported that DM is not a priority and that 
there is no national plan and no DR program in Akwa Ibom state (AKS) (see table 2).  
  
Table 2.0 Existence of priority, policies, programs and availability of clinical guideline for the 
management of DM and DR.          
Situation of DM and DR services in Akwa Ibom State  Frequency   %   
  
Existence of priority, policies and programs  
  
    
DM not a priority, no national plan, no program  
  
DM is a priority, there is national plan, no program implemented  
  
DM is a priority, there is a national plan but does not cover the whole country  
  
  
DM is listed as a priority; both a plan and a program are in place and there 
is national coverage  
  
Not aware if DM is a national priority, national plan and program  
15.0  
  
 2.0  
  
  
 0.0  
  
  




 2.0  
71.5  
  
  9.5  
  
  
  0.0  
  
  




  9.5  
  
Guidelines for clinical management of DR  
  
    
There are no Ministry of Health recommended guidelines  
  
Ministry of Health guidelines formulated, health professionals unaware of it, 
so they are not widely used  
  
Ministry of Health guidelines are available and known to the appropriate 
audience, but they are not widely followed  
  
  
Ministry of Health guidelines have been formulated and are commonly 
followed  
Not aware of the existence of Ministry of Health guidelines  
17.0  
  
  0.0  
  
  




  0.0  
  
  3.0  
81.0  
  
  0.0  
  
  











Similarly, most interviewed participants reported that DM and DR are not priorities, that there 
are no policies and programmes targeted at DM and DR, either at the national level or in AKS.  
Also, all interviewed participants reported that there is no national diabetic plan available in 
AKS. However, a director at the national level reported that there is no exclusive policy or plan 
on DM.  
“No. There is no exclusive policy on diabetes prevention… diabetes prevention activities are 
under the NCD Division”. (respondent 10)  
  
  
Participants attributed the lack of priority, policies and programmes to a variety of factors, as 
explored below:  
i. Lack of prioritising of DM and DR in the national health plan:   
  
Participants reported that the state health systems policies in Nigeria align with the national 
health policies;   
“The State will always align with the national, that is the federal ministry of health in this case.  
The national did not prioritize it so why would the state?” (respondent 2)  
ii. Lack of political will  
  
One of the participants offered the view that health priority, policies and programmes are 
influenced by the political class at the national level and in AKS. Most diabetic patients are 
aged and mostly apolitical and do not really have leverage to influence government policies in 
favour of DM and DR.   
“….in Nigeria each regime places emphasis on where it feels to be more important and for 
political gain. Most diabetic patients are the aged who do not have political influence.”  
(respondent 1)  
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 i.  The disease burden of DR in Nigeria in the context of blindness prevention efforts  
For some participants, the fact that DR is not the commonest cause of blindness in Nigeria 
means that it is normal that it should be less prioritized than, for example, cataract:   
“diabetic retinopathy but it is not a common cause of blindness here in Nigeria, so it is not 
something that we will say it is a priority in this part of the world…” (respondent 6)   
However, the absence of a State’s prevention of blindness plan in AKS is also believed to be 
responsible for the non-prioritization, lack of policies and programs for DM and DR.  “…the 
same negligence trickled down to the state because there is no prevention of blindness plan in 
Akwa Ibom State.” (respondent 9).  
 Clinical management guidelines  
  
81.0% of questionnaire respondents reported that there are no Ministry of Health recommended 
guidelines for the management of DR (Table 2.0).  
All participants interviewed agreed that there are no national consensus clinical guidelines for 
the management of DM and DR at all the levels of the health systems in AKS and Nigeria in 
general. Practitioners use guidelines from various sources they consider fit.  
“In Nigeria, there is no guideline but there are textbooks and online materials, you can 
reference…. So different individuals use different guidelines and materials online but at the 
end the same result is achieved.” (respondent 8)  
  
SERVICE DELIVERY, HEALTH WORKFORCE AND TECHNOLOGY  
  
Network and Linkages   
  
A total of 76.2% of participants reported that DR services are available in few places and to 
few people in AKS (see table 3.0).  
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Table 3.0 Location of DR services and accessibility to the population   
      
Situation of DM and DR services   Frequency of 
responses    
Percentages 
(%)  
Location of DR services and accessibility to population in need      
Services available in few places and few people  
  
Some services are available to part of the population  
  
Services are available everywhere but do not reach some of the 
population.  
Services are available everywhere for the population  
16.0  
  
  3.0  
  
  2.0  
  





  9.5  
  
  0.0  
Network between the care providers for DM and DR      
No known collaboration between separate providers of care of  
DM and DR  
Few centres provide patient centred care  
  
Some centres provide patient centred care by means of 
collaboration between DM and DR services              
                                              
Most centres provide patient centred care based on collaboration 
between DM and DR services  
  7.0  
  
  8.0  
  
  6.0  
  
  
  0.0  
 33.3  
  
 38.1  
  
 28.6  
  
  
  0.0  
  
Participants interviewed reported that DM and DR services are available only in the three 
General Hospitals (secondary hospitals), and the tertiary hospital (UUTH) situated in the urban 
areas. Basic DM services and DR screening are available in the general hospitals (secondary 
levels) while specialists services for DM and DR are available at UUTH (Tertiary level):   
“This facility, that is the University of Uyo teaching Hospital is the only tertiary hospital in 
Akwa Ibom State with specialist services like that of the endocrinologists…” (respondent 2)   
“…. Tertiary care levels, there is also a retinal specialist, …. we do not have any retinal 
specialist in any state general hospitals.” (respondent 4)  
Access to DM and DR services  
  
All participants reported that less than thirty percent (30%) of DM patients in AKS has access 
to DR services. Their reasons for poor access to DR services were categorized into:   
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i) Lack of awareness: Many DM patients are not aware of the ocular effects of 
DM. Some believes that blindness is inevitable in old age, and so they do not seek 
treatment for DR early.  
ii) Traditional medications: Some DM patients believe that traditional medication 
is cheaper and can be used for multiple eye conditions, and this belief leads some 
patients to seek traditional medication instead of DR care in the hospitals.  
iii) Inadequate health workforce / lack of specialists: DR care providers are few and 
not evenly distributed in AKS which hinders access to DR care.  
  
Participants reported that the categories and number of health workers involved in DM and DR 
care in AKS are inadequate. Participants reported a total of eleven (11) optometrists (7 with 
AKS civil service and 4 with the UUTH), seven (7) ophthalmologists (five with the UUTH and 
two with the AKS civil service), four (4) ophthalmic nurses, two endocrinologists with UUTH 
and above one hundred (100) medical officers in government hospitals in AKS as the main 
categories of workers involved in DM and DR services in this state.  
“…. From my records, Akwa Ibom State civil service has 10 optometrists, 2 ophthalmologists 
and above hundred (100) medical officers. We do not have ophthalmic nurses and 
endocrinologists here, but the teaching hospital has.” (respondent 9)  
“… here at the teaching hospital, we have two endocrinologists, that is the report from the 
Endocrinologist unit… there are four (4) optometrists, five (5) ophthalmologists which one of 
them is a retinal specialist, four (4) ophthalmic nurses…” (respondent 5)   
Participants reported that the specialists involved in DR and DM care are situated in UUTH in 
the state capital, while eye units for DR screenings are available in only three general hospitals 
situated in the town.    
Participants attributed shortfall in the workforce to lack of employment by the government, 
absence of diabetic centre in Akwa Ibom State and lack of training opportunities for providers.  
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Questionnaire findings showed that 42.9% of respondents reported that workforce training 
opportunities in AKS are largely inadequate, 42.9% reported few training opportunities 
consequently fewer human resources than needed, 9.5% reported that training is only available 
in large cities and hospitals while 4.7% reported that training for DM and DR is appropriate 
and of good quality (see Table 4.0).  
Table 4.0 Training opportunities and quality for DM and DR services   
      
Training opportunities and quality for DM and DR services  
  
Frequency 
responses   
of  Percentages (%)  
       
Largely inadequate.  
  
  
Few training opportunities, consequently fewer human 
resources than needed.  
  
  
Training available only in large cities and hospitals.  
  
  



















  9.5  
  
  
  4.7  
  
iv)  Lack of basic infrastructures and equipment: retinal imaging cameras and lasers are not 
available in the government hospitals in AKS.   
“…. We do only direct ophthalmoscopy, no instruments and equipment like the indirect 
ophthalmoscope, OCT …. I am limited with only direct ophthalmoscopy.” (respondent 8)  
Among the questionnaire respondents, 61.9% reported that modern examination technology 
for DM and DR is not available for a majority of the patients. 33.3% reported that modern 









Table 5.0 Accessibility of modern technology for DM and DR services       
Health Technology    Frequency of 
responses   
Percentages 
(%)  
Accessibility  of  health  technology 
 (modern technology)  
examination      
  
Not available for the majority of the patients  
  
Available only in major hospitals and private clinics  
  
Available in most provincial hospitals and clinics  
  
Available to all patients  
   
 13.0  
  
   7.0  
  
   0.0  
  






  0.0  
  
  4.8  
  
Participants reported that the basic technology required for DM investigation is available in the 
general hospitals and UUTH, but dialysis machine is available only in UUTH.   
 “Every hospital should have the glucometer at least and should be able to carry out the urine 
test. There is a dialysis machine at the teaching hospital.” (respondent 3)  
However, most participants reported lack of modern technology for DR examinations in AKS. 
They reported that the instruments available for DR services in Akwa Ibom State include:  
Slit lamp and direct ophthalmoscope are available in UUTH and in three general hospitals 
which provides eye care services. Indirect ophthalmoscopes are only available in UUTH. There 
is no laser technology and retinal imagine technology in any government hospital in AKS.  
 “we don’t have lasers in this hospital and I am sure the other government hospitals don’t have 
equally.” (respondent 6)  
v) Prohibitive cost of DR services: the cost of injections, lasers and testing with OCT is high 




“…. the cost of treatment also is a problem to some people because the injection I was 
mentioning that could be given here are expensive the cheapest ones are like maybe 40,000 
naira that the patients must take every month and the NHIS doesn’t cover it.” (respondent 6) 
vi) Distance to care: DR management services is only available in UUTH, so all DR patients 
need to travel to UUTH for care, which discourages access to DR care.  
“The location of the teaching hospital in Uyo means that the people in the rural areas cannot 
have access to diabetic retinopathy services.” (respondent 9)  
 Networks between the care providers for DM and DR  
  
None (0%) of the questionnaire respondents agreed that most centres provided patient centred 
care based on collaboration between DM and DR services (see Table 3.0).  
Similarly, interviewed participants reported lack of both routine and reciprocal referral systems 
between diabetes and eye units. The eye unit refers patients to diabetes clinic when they suspect 
DM and diabetes providers refers DM patients to eye unit only when they have eye complaints 
(see Table 3.0).  
DM and DR provider networks are affected by:  
i. Workload: Some participants feel that access is reduced due to inadequate workforce caring 
for diabetics and the disparity in clinic days between the diabetes units and eye units, the extra 
financial burden for patients, as well as long waiting times.   
“…. people with diabetes are not routinely referred for eye examination except when they have 
eye related complaints. I know that they should be referred routinely but do to workload I do 
not until any patient complain of eye problems. If you also consider that such patients will have 
to come back another day for eye clinic. In the eye unit the patient will be required to start 
registration afresh, buy another patient card, join the queue and pay transport to and from a 
17  
  
far location for an asymptomatic condition you might just decide that it is not necessary till the 
patient complains.” (respondent 2) ii. Apathy by the health workers managing diabetes: one 
participant reported routine referral is not necessary.  
“…. I do not think that it is necessary to refer diabetes patients except if they complain about 
their vision.” (respondent 3)  
 
          HEALTH INFORMATION MANAGEMENT SYSTEM  
  
Follow up and recall systems   
  
Reports of follow up and recall of patients to have their eyes tested using hospital information 
card which contains patients follow up appointment days was reported by all participants.  
Knowledge of disease burden  
  
A total of 71.4% of the questionnaire respondents reported that prevalence of DM and DR is 













Table 6.0 Knowledge of disease burden   
Situation of DM and DR services in Akwa Ibom State  Frequency of Percentages 
responses  (%)  
Knowledge of disease burden      
  
Prevalence of DM and DR is neither known nor estimated.  
  
  
Prevalence of DM is known but not the prevalence of DR.  
  
  




Prevalence of both DM and DR is known or has been estimated; 
patients’ data is used to analyse data at the national level  
 
Prevalence of both DM and DR is known or has been estimated; 





  2.0  
  
  




  1.0  
  
  





  9.5  
  
  




 4.8  
  
  
 4.8  
  
However, interviewed participant reported that both incidence and prevalence of DM is 
monitored in AKS via data collected from the patient folders in health facilities:  
“…. both incidence and prevalence are monitored…. in this facility we do it annually… in this 
facility data are collated from patients’ folders by the record keepers. These data are entered 
into a standardized broadsheet capturing the required variables. The standardized broadsheet 
is sent to the Federal Ministry of Health for planning, budgeting and policy making.” 
(respondent 2)  
All participants also reported not being aware of agreed health indicators for monitoring DR in 
AKS.  
  
   HEALTH PROMTION FOR DM AND DR  
  
All participants reported that awareness for the DM and DR in AKS is carried out through the 
diabetes support group/ association in meetings, World diabetes days and World sight days.  
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 “Yes. During our support group meetings, we do invite the ophthalmologists for lectures and 
they do talk about diabetic retinopathy.” (respondent 1)  
 “World sight day, we go on radio, television to create awareness. Apart from that, we also 
actually go to rural areas to give health talk and to do eye screening, general eye screening 
not particularly, we pick up some cases of diabetic retinopathy, but we do general eye 
screening for eye problems including diabetic retinopathy.” (respondent 5)  
Health promotion for the disadvantaged and disabled in the communities.  
  
Regarding awareness for DM and DR, it is made accessible to the disadvantaged groups of the 
population through the mass media, the use of the local dialects and the use of special doctors:  
“…. patients’ support organization is made accessible to disadvantaged groups of the 
population through radio and television awareness programmes in the Efik and Ibibio 
languages…we have a doctor who is a specialist in sign language, he interprets for the deaf 
and dumb.” (respondent 4)  
  
  
  HEALTH INFORMATION FOR DM AND DR IN THE COMMUNITIES.  
  
A total of 66.7% of the questionnaire respondents reported that little information is provided 







Table 7.0 Information and education provided to the community and to patients on DR and 
DM.  
      





Information/education provided to the community and to patients on 
DM and DR  
    
Little information is provided to the community and patients.   
  
Information to the community is produced occasionally and only 
through national level media; not all patients receive education.  
  
Information is provided at national and provincial level; most patients 
receive education.  
  
Information is provided to the community at all levels; all patients 
receive education and patients are actively involved  
14.0  
  
  2.0  
  
  
  3.0  
  
  
   2.0  
66.7  
  
  9.5  
  
  
 14.3  
  
  
  9.5  
  
Participants reported that the factors constraining DM and DR health promotion activities in 
AKS are the lack of access to diabetes support group to the rural population and the lack of 
diabetes specialists in general hospitals and NGO hospitals.  
 
 
HEALTH FINANCING FOR DM AND DR.  
  
  
Among the twenty-one (21) participants in the questionnaire, 57.1% reported that there is no 
financing for DR and DM services- patients pay out of pocket for all services. 23.8% reported 
that government through the NHIS provide some financing - patients pay out of pocket for 
some services, while 19.1% reported not to be aware of how DR and DM services are financed.  






Table 8.0 Health financial interventions for DR and DR services  
      
Situations of DM and DR services in Akwa Ibom State  Frequency 
responses   
of  Percentage (%)  
Health financing Interventions        
  
No financial intervention for DR and DM services; patients pay 
out of pocket for all services.   
  
Government through the national health insurance scheme 
(NHIS) provide some financial intervention; patient pay out of 
pocket for some services.  
  
NGO’s provide some financial intervention; patient pay out of 
pocket for some services.  
  
Government and NGOs mostly provide financial interventions 
for DR and DM services  
  






  5.0  
  
  
  0.0  
  
  
  0.0  
  
  
  4.0  








 0.0  
  
  





Reports from interviewed participants corroborated the questionnaire findings. Patients 
majorly pay out of their pocket for DM and DR services in AKS with little government 
financial intervention under the national Health Insurance Scheme (NHIS). NHIS only captures 
civil servants active in AKS and federal government.  
 “… the national health insurance scheme covers 90 percent of the expenses while the patients 
under this insurance pay 10 percent. The NHIS covers some medications though and some 
services. However, most people are not covered by the NHIS, so they pay out of their pocket. 
In Nigeria and Akwa Ibom state for now, interventions for people with diabetes is majorly 







Our findings suggest gaps in several components of the health system that need strengthening 
to better serve patients with DR.   
Low priority, lack of policies and programmes towards DM and DR and lack of consensus 
about clinical management guidelines for DM and DR entails that DM and DR care is neglected 
in AKS and that DM and DR care is not part of the AKS health care agenda. This neglect could 
lead to catastrophic trend of DM epidemics resulting in high prevalence of blindness from DR 
in the nearest future.24, 25 Systematic reviews have reported lack of national policies, low 
priority of DM and DR in the national health agenda and lack of consensus clinical 
management guideline as responsible for the catastrophic trend of DM epidemics and high 
prevalence of DR in sub- Saharan Africa (SSA).24, 25    
Non-availability of DM and DR services at the primary health level and rural areas, 
noncollaboration between providers of DM care and DR care, lack of reciprocity in referral of 
patients suggests lack of patient centred care in AKS. Studies have reported that DR detection 
and management services are important but only exists in urban settings. Poor organisation of 
referral pathways between the primary level, secondary level of care, providers of DM care 
and eye care are part of the gaps of DM and DR systems in SSA.21, 24 In SSA, DM occurs 
mostly in the urban and peri-urban areas and therefore these areas need DR prevention services 
the most.26 Our study did not cover prevalence of DM and DR per area in AKS.  
A lack of workforce for DR and DM is not unique to AKS but is a challenge observed in many 
low and middle-income countries. The fundamental challenge to the increasing blindness rate 
from DR globally is the lack of access to high-quality ophthalmologists, with most 
ophthalmologists available only in big cities.16 This is similar to DM and DR workforce  
situation in SSA which hinders access to quality care.21, 24  
23  
  
Lack of modern technology for DR screening and diagnosis in AKS suggests the likelihood of 
misdiagnoses, increased visual impairment and blindness from DR.21  
Nonexistence of a formalized health information management systems for DM and DR 
suggests that the lack of standardized data probably responsible for the lack of DR policies in  
AKS.20  
 
Inadequate patient education on DM and DR in AKS suggests that patients may not be 
proactive with the prevention of DM and DR, and in accessing other DM and DR services due 
to ignorance and late presentation, resulting in more complications and blindness. Especially, 
those in the rural areas who cannot access the support group in the tertiary hospital situated in 
Uyo the urban centre of AKS, this type of situation has similarly been reported by other authors 
in other poor resource settings.21, 27   
A high proportion of out of pocket payment for DR and DM services would have discouraged 
patients from accessing care in AKS.28 Studies have reported lack of health insurance as a 
barrier to take up eyecare.28-30 The government of AKS needs to cover every patient under the 
NHIS to reduce the financial burden associated with DM and DR care.  
During the 1980s, low income countries, such as, India couldn't manage eye problems, 
especially cataract. Then, India accounted for about 33% of the world's blind population.31 
India couldn't manage eye problems, especially cataract, because it was of low priority at the 
time, also, they lacked skilled eye care professionals and had obsolete technology. Cataract 
blindness in India accounted for 80 percent of all blindness compared to a global proportion of 
50% at that time. 16, 31, 32 India was doing only about 1.5 million cataracts yearly then, most of 
the surgeries were done in field/makeshift rooms in the rural areas, and often not by a specialist 
and with unacceptable results.  Be that as it may, in the early 1990’s, India collaborated with 
Non-governmental organisations (NGO's), global agencies like the World Bank, instituted eye 
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care friendly policies, and eye care service models thus eye programs prospered even over 
infectious and diarrheal diseases.16   
In 1995, the Indian government propelled a seven-year plan– the Cataract Blindness Control 
Project sponsored by the World Bank. This project resulted to countrywide improvement in 
surgical innovation leading to about 15.3 million cataract surgeries performed, of which 
women and tribal population constituted more than 50%. About 842 ophthalmic surgeons were 
trained in performing cataract surgery using new technology with improvement in pre and post- 
surgical care using the new technology. This project also resulted to significant infrastructural 
strengthening, including the development of 301 operation theatres and 273 eye wards. 
Furthermore 45 medical colleges, 259 district hospitals, 254 district mobile units and 3281 
primary health centres were provided with eye-care equipment, including 747 operating 
microscopes, 600 slit lamps, 821 A-Scans, 344 AVUs, 681 keratometers, and 178 Yag lasers.31  
The cataract blindness control project presented new assessment tools, which the National 
Program Management Cell used to monitor implementation and outcomes. Management of the 
cataract blindness control program was established at the central, state, and district levels. The 
project raised public awareness about cataracts as curable and the advantages of the new 
surgical technology.31 
India also pioneered the cross-subsidization model for eye care, where fees from wealthier 
patients helped cover the costs of treatment for the poor. Aravind and other hospitals charged 
fees on a tiered scale according to how much a patient can pay. Aravind covers all its expenses 
with this model. In this model, effective and efficient collaboration with “allied ophthalmic 
personnel” — nurses, technicians, and assistants — who do the initial evaluations, enabled 
hospitals to carry out large number of surgeries daily. Most of the major hospitals developed 
their own training programs for eye care support staff. 16, 32  
25  
  
Globally, India has one of the highest number of diabetics.27 India and surrounding states face 
many of the same barriers to DR care recognized in Africa: lack of resources and trained 
manpower to screen and treat the large number of people with DR; unequal distribution of 
resources between urban and rural areas; and populations with high levels of poverty and poor 
education many of whom are remote from health services.21 India have utilized varieties of 
screening and treatment models involving advances in information, medical and 
communication technology to reduce inequalities in service delivery including  connecting  
diabetics to DR services.26  Also, economic modelling analysis showed that their rural 
teleophthalmology program where screenings are done in the rural area  with cameras  and 
fundal images  transferred to a specialist was cost effective compared to no screening.33  
Sustainable models of screening and treatment for DR in Africa and Nigeria could be modelled 
on those already operational in India. 
The strength of this study was that all stakeholders involved are all experienced in management 
and policy making with regards to DM and DR in AKS. The use of both qualitative and 
quantitative methods provided a better understanding of the situation.    
The limitation was that patients were excluded because during the time of this research, 
government hospitals in Nigeria were on strike. Patients’ opinions should be explored also.   
The present situation of DM and DR services in AKS requires advocacy by the stakeholders 
for prioritization of DM and DR by the government, decentralization of DR and DM services 
to the primary level, employment of more specialists and training of other health workers on 
how to screen for DR, provision of the modern technologies for DR and DM, and more 
importantly, formulation of policies for DR and DM by all stakeholders.  
The results from this study has provided evidence on the present DM and DR gaps in AKS, 
which will inform stakeholders and policy makers on where to strengthen to better serve 
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 Appendix 2:  Informed consent to participate in a research   
  
Title of Research Project: HEALTH SYSTEMS ANALYSIS OF DIABETES AND DIABETIC 
RETINOPATHY SERVICES IN NIGERIA: The case of Akwa Ibom State   
  
Contacts:  
• Name of Investigator: Stephen Maduabuchi Samuel          
             Phone Number of Principal Investigator: +234(0)8122042244   
  
• University of Cape Town  
             Faculty of Health Sciences  
             Human Research Ethics Committee  
             Room E53-46 Old Main Building  
             Groote Schuur Hospital  
             Observatory 7925  
             Telephone [021] 406 6626   
             Email: shuretta.thomas@uct.ac.za  
             Website: www.health.uct.ac.za/fhs/research/humanethics  
  
  
A. PURPOSE AND BACKGROUND   
  
Stephen Maduabuchi Samuel, a Master of Public Health Student in the University of Cape  
Town South Africa is conducting a research on THE HEALTH SYSTEMS ANALYSIS OF DIABETES 
AND DIABETIC RETINOPATHY SERVICES IN NIGERIA: The case of Akwa Ibom State. The 
purpose of your participation in this research is to help the researcher: To investigate and 
analyse the situation of diabetes (DM) and diabetic retinopathy (DR) services in government 
hospitals in Akwa Ibom State (AKS) Nigeria using the World Health Organisation (WHO) 
health system framework.  
   
  
  
B. PROCEDURES   
  
If you agree to participate in this research study, you will be interviewed and will also be a 
given a questionnaire to fill, which will cover leadership and governance, service delivery, 
health workforce, health information management systems, financing, medical products and 
technologies involved in the management and care of diabetes and diabetic retinopathy in 
Akwa Ibom State. The interview will be conducted face to face, telephonically or via skype 
depending on your preference. Interviews will be recorded with a tape recorder for 
transcription. The interview is expected to last for one hour on average for each participant. 
The questionnaires will be administered face to face or via the internet depending on your 





C. RISKS   
  
This study does not pose a physical risk or medical risk to the participants. However, the 
participant might face the risk of being sanctioned for giving out sensitive information 
concerning understaffing/ lack of staff, inadequate/lack of infrastructures or ineffective health 
systems generally which are mostly political issues in Nigeria.   
  
D. CONFIDENTIALITY   
  
Personal identifiable details will not be collected during the interviews and Surveys. Data will 
be coded by the researcher. The research data, electronic and hard copy, will be stored in a 
password protected computer and, in a password, protected external computer hard disc as 
back up. Only the researcher will have access to the data. On completion of analysis, after 
manuscripts have been accepted for publication, the analysed dataset will be returned to 
University of Cape Town for secure archiving while the copy on the student`s computer will 
be permanently deleted  
  
E. BENEFITS OF PARTICIPATION   
  
There will be no direct benefit to you for participating in this research study. However, this 
research will benefit the health system generally through the recognition of the gap that are 
required to be filled for effective, holistic management of diabetes and diabetic retinopathy in 
Akwa Ibom State. The findings from this research will be used to advocate for more attention 
in the prevention, management and care of diabetes and diabetic retinopathy in Akwa Ibom 
State Nigeria. Other researchers will also benefit from the findings from the research for 
further researches.   
  
  
F. VOLUNTARY PARTICIPATION   
  
Your decision whether to participate in this research is voluntary and will not affect your 
relationship with the researcher. You can also withdraw your consent and discontinue 
participation at any time without prejudice.   
  
  
G. QUESTIONS   
  
If you have any questions or concerns about this study, please contact  
  
• Stephen Maduabuchi Samuel by calling 08122042244  
  
 or   
  
• University of Cape Town  
23  
  
             Faculty of Health Sciences  
             Human Research Ethics Committee  
             Room E53-46 Old Main Building  
             Groote Schuur Hospital  
             Observatory 7925  
             Telephone [021] 406 6626   





H. COMPENSATION   
  
There will be no financial compensation for participating in this research.   
  
  
CONSENT   
  
You are deciding whether to participate in a research study. Your Signature below indicate that 
you have decided to participate in the study after reading all the information above and you 
understand the information in this form, have had any questions answered and have received 
a copy of this form for you to keep.   
  
Research Participant’s Signature _________________________ Date __________________   
  















 Appendix 3: key informant interview guide  
  
The key informant interviews will be semi-structured and open ended to gain an in-depth 
understanding of the situation of DM and DR services in Akwa Ibom State. The interview 
guide follows the structure of the World Health Organisation (WHO) tool for the assessment 
of diabetes and diabetic retinopathy services.  
Some of the questions are more relevant to stakeholders at the Federal and State Ministries of   
Health (e.g. development of diabetes policies, programmes and guidelines) while others are more 
relevant for the medical personnel (e.g. service delivery).  
The main questions under each topic are already included in the WHO TADD  
(questionnaire). More questions will arise from the response of the respondents and we will 
use face to face interviews with the respondents to explore the ‘’whys’’ and “hows”. The 
semi structured interviews format complements the WHO tool and will lead to a more 
rigorous analysis of the challenges and opportunities for improvement associated with the 
management of DR in Akwa Ibom State.   
  
Priorities, Policies and Programmes  
In this section, the tool contains questions related to policies and programmes for DM and DR, 
with questions like:  
  
• Does your country have a national diabetes plan (yes/no)?  
• Is diabetic retinopathy (DR) listed as a priority in the national prevention of blindness plan 
(yes/no).   
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In our follow-up questions we will ask the respondents to expand their initial answers. For 
example, if DR is not listed as a priority in the national prevention of blindness plan, why is 
that so? Is there available evidence about the prevalence and burden of DR in Nigeria and 
Akwa Ibom State? If DR is listed as a priority, what resources are available to address this 
priority and how are these resources deployed (example training and continuing medical 
education, new DR programmes etc) as part of the implementation of the national prevention 
of blindness plan?  
Service delivery  
In this section, the tool contains questions related to how DM and DR services are delivered, with 
questions like:  
• What services are available people with diabetes? Where can they access these services 
(screening, diagnosis and management)?  
• Are people with diabetes routinely referred for eye examinations? If not, why? What 
referral systems/pathways exist between DM and DR services?  
• How many public (government) hospitals provide diabetes and DR services in Akwa  
Ibom State? Any information regarding their capacity to provide eye care?  
• What equipment is available in the public (government) hospitals for the management of 
DM and DR services in Akwa Ibom State?  
Follow up questions will require the respondents to expand on the questions to give insight on 
the factors that enable or constrain service delivery, and what recommendations they have to 
improve service delivery.  
Health workforce  
In this section, the tool contains questions related to the cadres, numbers, distribution and training 
of staff involved in diabetes and eye care services.  
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• What categories of medical/ health personnel are involved in the management of DM and 
DR?  
• Can you estimate the number and distribution of these medical/ health personnel 
including registered ophthalmologists (including vitreoretinal surgeons and medical 
retinal specialists), internal medicine physicians, general practitioners, nurses, 
optometrists?  
• What aspects of diabetes are included in the teaching curriculum for primary health care 
workers (nurses and primary care physician)?  
We will ask respondents to identify priorities for strengthening human resources for eye health 
in Nigeria, including for DR management.  
  
Health information management systems  
This section will cover questions like:  
• What nationally agreed health population indicators of diabetic retinopathy are?  
• Monitored, and how are the data collected? What methods are used, if any for sharing 
patient data between providers of health care services?  
• Is there a recall system for people with diabetes to have follow-up eye examination? The 
interviewees will be asked to identify gaps and recommendations to improve health 
information systems for DM and DR.  
  
Health promotion for diabetes and diabetic retinopathy  
Health promotion questions for DM and DR services will be asked in this section. Questions  
like:  
• Is information provided to the community about diabetic retinopathy? if yes, how? 
Could you provide us with the titles and details of public health materials used for 
community awareness or patient education?  
27  
  
• Are World Sight Day and World Diabetes Day used as opportunities for major 
awareness raising initiatives?  
  
Health financing   
Issues related to the financing for DM and DR services will be raised in this section of the tool. 
Issues like:  
• Coverage (% of population) of population with government health insurance for diabetes 
detection, monitoring and treatment?  
• Coverage (% of population) of population with private health insurance?  
• List of items / services that can be claimed under government health insurance for diabetes 
and eye care?  
• How are interventions for people with diabetic retinopathy financed?  
Follow up questions will be based on the responses of the respondents. We will seek to 
describe the current funding (private and public) situation for DM and DR, by stream 












Stephen Maduabuchi Samuel a Master of Public Health Student at The University of Cape 
Town South Africa Is Carrying Out a Research titled: Health Systems Analysis of Diabetes 
and Diabetic Retinopathy Services in Nigeria; the case of Akwa Ibom State.   
  
He Is Seeking to Recruit Stakeholders/Medical and Health Workers Involved in Diabetic and 
Diabetic Retinopathy Services in Government Hospitals in Akwa Ibom State to Participate In 
this Research.   
Each Participant will be required to fill a Questionnaire which will leadership and 
governance, service delivery, health workforce, health information management systems, 
financing, medical products and technologies involved in the management and care of 
diabetes and diabetic retinopathy in Akwa Ibom. The questionnaire is expected to be 
answered within 30 minutes.  
There will be NO financial compensation for participating in this research study.  
  
If you wish to participate in this research, please contact:  
Stephen Maduabuchi Samuel   
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Appendix 8:   Instructions for Authors (Ophthalmic Epidemiology).
The following are the files need to make your online submission complete:  
I. MANUSCRIPT FILE
1. Cover page –
a) list the title of your submission – no abbreviations or acronyms (acronyms
may be considered if important for recognition of a prominent study, and in
that case,  they should be used only after defining the acronym in the title)
b) supply a running head -  a shortened version of title, not to exceed 50
characters.  If the full title is 50 characters or less, they can be the same.
c) All authors of a manuscript should include their full name and affiliation on
the cover page of the manuscript.
d) indicate who is the corresponding author and the corresponding contact
information (especially email),
e) financial support – list all financial support
f) list any proprietary interests or conflicts of interest for any and all authors
related to this submission.  “If none, please state:  None of the following
authors have any proprietary interests or conflicts of interest related to this
submission:”; then list all the authors with no such interests.  “None of the
authors” suffices if no one has any such interests.  Please err on the side of
disclosure if it is unclear whether something is an interest or not, and
please include relationships that may be perceived by others as a conflict
of interest.
g) statement that this submission has not been published anywhere
previously and that it is not simultaneously being considered for any other
publication.   Note:  if the paper previously has been reviewed and rejected
by another journal, please indicate so, and please indicate what criticisms
were given and what changes have been made in response (as if you were
revising and resubmitting to the original journal).  We are open to accepting
such papers if they have merit, and there is no need to hide this
information.
2. Abstract – start on new page – not to exceed 250 words, define all abbreviations





3. Manuscript text – start on a new page.  The text should not exceed 4,000 words.
Define all abbreviations and acronyms at first use (even if previously defined in
abstract).  The text should be divided into the following 5 sections:
a) Introduction—give the rationale for why this manuscript is important
b) Materials and Methods – should include a statement regarding adherence
to the guidelines of the Declaration of Helsinki as well as giving the name of
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the Institutional Review Board which granted approval, or which indicated 
approval was not needed.  Any waivers granted, such as HIPAA waivers or 
waiver of consent, should be mentioned.  Whether patients consented to 
participate in the study should be mentioned; if not, the reason why not 
should be mentioned (e.g., Institutional  
Review Board waiver of consent)  
c) Results—summarize the key and supportive results in a clear, crisp,
straightforward manner.
d) Discussion—discuss what the key findings are, how it fits in with existing
knowledge on the subject, and if their alternative explanations of the
observations such as bias or random error.  Please include a strengths and
limitations paragraph, as well as a concluding paragraph summarizing the
main items of knowledge that the paper has provided and relevant
applications.
e) References – Please follow the directions in Section 4 below.
4. References - cite in the text as superscript by reference number, consecutively
as they appear in the text, starting with 1.   Prepare a numbered reference list.
Only published and accepted (in press) articles can be cited.   Abstracts should
be cited parenthetically within the text as should any personal communication or
unpublished data.  Submitted articles are not citable and should be referenced as
unpublished data.
PRE-EDIT: AMA 
AMA (AMA Manual of Style, 10th ed.) 
References should be presented in a separate section at the end of the document, in 
accordance with AMA Manual of Style (10th ed.) guidelines. The references should 
be listed and numbered based on the order of their first citation. Every reference 
should be assigned its own unique number. References should not be repeated in 
the list, with each mention given a different reference number, nor should multiple 
references be combined under a single reference number. Superscripted digits 
should be used for in-text citations Superscripted citations should only follow terminal 
punctuation (e.g., periods, commas, closed quotation marks, question marks, 
exclamation points). Reference numbers should not be subscripted.  
Author listings in references should be formatted as indicated below. 
1 author Smith A. 
2 to 6 authors Smith A, Jones B, Smythe C, Jonesy D, Smitty E, Jonesi F. 
7 or more authors Smith A, Jones B, Smythe C, et al. 
Models from US National Library of Medicine (NLM) resources (e.g., MEDLINE, 
Index Medicus) should be employed for abbreviating journal titles in the reference 
section. Examples of common reference types appear below.  
Journal article 
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12. Taylor J, Ogilvie BC. A conceptual model of adaptation to retirement among
athletes: a meta-analysis. J Appl Sport Psychol. 1994;6(1):1–20.
doi:10.1080/10413209408406462.
Book 
2. Duke JA. Handbook of Phytochemical Constituents of GRAS Herbs and Other
Economic Plants. Boca Raton, FL: CRC Press; 2001.
Book with titled volume and edition 
18. Bowlby J. Loss: Sadness and Depression.Vol. 3 of Attachment and Loss. 3rd ed.
New York, NY: Basic Books; 1982.
Edited book chapter 
34. Gordon S, Lavallee D. Career transitions in competitive sport. In: Morris T,
Summers J, eds. Sport Psychology: Theory, Applications and Issues. 2nd ed.
Brisbane, Australia: Wiley; 2004:584–610.
Edited book chapter with volume and edition 
26. Remael A. Audiovisual translation. In: Gambier Y, van Dooslaer L, eds.
Handbook of Translation Studies. Vol. 1. 2nd ed. Amsterdam, Netherlands:
John Benjamins; 2012:12–17.
Online/Website 
8. United States Census Bureau. American housing survey: 2013 detailed tables.
United States Census Bureau Web site.
http://www.census.gov/newsroom/press-releases/2014/cb14-tps78.html. Published
October 16, 2014. Accessed October 21, 2014.
Dissertation/Thesis 
26. Allison N. Bacterial Degradation of Halogenated Aliphatic Acids [dissertation].
Nottingham, UK: Trent Polytechnic; 1981.
Conference presentation 
4. Alfermann D, Gross A. Coping with career termination: it all depends on freedom
of choice. Paper presented at: 9th
Annual World Congress on Sport Psychology; January 23, 1997; Netanya, Israel. 
Paper/Report  
55. Grigg W, Moran R, Kuang M. National Indian Education Study. Washington DC:
National Center for Education Statistics; 2010. NCES publication 2010-462.
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Newspaper 
22. Protzman, F. Clamor in the East: East Berliners explore land long forbidden. New
York Times. November 10, 1989: A1, A14.
Patent 
67. Pfeifer A, Muhs A, Pihlgren M, Adolfsson O, Van Leuven F, inventors; AC
Immune S.A, Katholieke Universiteit Leuven, assignees. Humanized tau
antibody.  US patent 9,657,091. May 23, 2017.
Computer software with developer 
10. Noguera J, Cumby C. SigmaXL [computer software]. Version 8.0. Kitchener,
Canada: SigmaXL, Inc; 2017.
Computer software without developer 
76. SPSS Amos [computer software]. Version 22.0. Armonk, NY: IBM; 2013. Dataset
3. Wang, G-Y, Zhu Z-M, Cui S, Wang J-H. Data from: glucocorticoid induces
incoordination between glutamatergic and GABAergic neurons in the amygdala
[dataset]. Dryad Digital Repository. https://doi.org/10.5061/dryad.k9q7h. Published
August 11, 2017. Accessed December 22, 2017.
II. Tables and Figures: Tables and figures should not be embedded in the text
but should be included as separate sheets or files. Each figure and table should be a
separate file uploaded into the system.  A short descriptive title should appear above
each table with a clear legend and any footnotes suitably identified below. All units
must be included. Figures should be completely labelled, taking into account
necessary size reduction.
Figure captions should be typed, double-spaced, in a separate file. All non-electronic 
original figures should be clearly marked with the number, author’s name, and top 
edge indicated.  If you are contemplating submitting non-electronic material, please 
contact the editorial office to discuss whether this can be permitted, and to arrange 
how to do so.  Non-electronic material should be used only if it is impossible to 
submit electronically, and if the material adds value to the manuscript.   
III. Illustrations: Illustrations submitted (line drawings, halftones, photos,
photomicrographs, etc.) should be clean originals or digital files. Digital files are
recommended for highest quality reproduction and should follow these guidelines:
· 300 dpi or higher
· sized to fit on journal page
· EPS, TIFF, or PSD format only
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Colour Reproduction: Colour art will be reproduced in colour in the online 
publication at no additional cost to the author. Colour illustrations will also be 
considered for print publication; however, the author will be required to bear the full 
cost involved in colour art reproduction. Please note that colour reprints can only be 
ordered if print reproduction costs are paid. Print Rates:  $400 per figure for the first 
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